No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARVN240517P30000
- 0.70
- -0.05-6.67%
15min DelayClose May 9 16:00 ET
0.73High0.60Low
0.65Open0.75Pre Close13 Volume401 Open Interest30.00Strike Price866.00Turnover89.67%IV-8.76%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.70Time Value100Contract SizeAmericanOptions Type-0.2931Delta0.0802Gamma37.59Leverage Ratio-0.0911Theta-0.0021Rho-11.02Eff Leverage0.0165Vega
Intraday
- 5D
- 1D
News
Express News | Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (Esmo) Breast Cancer Annual Congress
Arvinas Is Maintained at Overweight by Wells Fargo
Arvinas Is Maintained at Overweight by Wells Fargo
Express News | Arvinas Inc : Wells Fargo Cuts Target Price to $60 From $63
Buy Rating Affirmed on Arvinas With Promising Trial Updates and Robust Financial Outlook
Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Arvinas, Inc. (NASDAQ:ARVN) last week reported its latest first-quarter results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Arvinas Holding Company (ARVN) and UniQure (QURE)
Comments
Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28% 1
Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.
1
$Arvinas(ARVN.US$ 👀 new hoy
$Arvinas(ARVN.US$ I hope everyone bought that sub 14 dip! This thing has been a beast.
1
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more